Migraine
Mindfulness-based stress reduction has long-lasting benefits for migraine
Mindfulness-based stress reduction appeared to safely treat total migraine burden with long-lasting effects, according to findings presented at the annual meeting of the American Neurological Association.
Migraine may increase risk for retinal artery occlusion
Top in endocrinology: Midlife migraine, weight loss goals in diabetes
Research presented at the North American Menopause Society annual meeting suggests that hormones play a role in midlife migraine attacks among women.
Midlife migraines ‘treatable,’ but team-based approach needed
The cause of midlife migraines in women is likely multifactorial, though research suggests that fluctuating hormone levels may play a role, according to a speaker at the North American Menopause Society annual meeting.
Migraine significantly worsens sleep quality, architecture
Individuals with migraine had much poorer subjective sleep quality and altered sleep architecture vs. healthy individuals, according to results of a meta-analysis published in Neurology.
Target young women with migraine for increased cardiovascular risk prevention
Women with migraine headaches should receive targeted atherosclerotic cardiovascular disease prevention, including attention to safer contraception and safe menopausal hormone therapy, beginning in young adulthood, according to a speaker.
Perimenstrual migraine attack duration affects recurrence risk, triptan use
Longer duration of perimenstrual migraine attacks among women with menstrual-related migraine appeared linked to increased recurrence risk and triptan use, according to results of a prospective study published in Neurology.
FDA approves DHE-based migraine treatment Trudhesa
The FDA approved dihydroergotamine mesylate for the treatment of adults with acute migraine with or without aura, according to a press release from the drug’s manufacturer.
Virtual roller coaster simulation shows impact of migraine on visual motion stimuli
Migraine correlated with “abnormal modulation” of visual motion stimuli in different areas of the brain that further related to migraine disability and motion sickness susceptibility, according to findings published in Neurology.
Vyepti demonstrates efficacy in patients with migraine
Among patients who experienced a moderate to severe migraine attack, IV treatment with Vyepti shortened time to headache and symptom resolution compared with placebo, according to results from a randomized clinical trial.